Larvol Delta - Marker-Therapeutics-Reports-PreClinical-Data-of-its-MT601-MultiTAASpecic-T-Cell-Product-Candidate-in-Lymphoma-Cells

MT-601 - Marker Therap

https://www.globenewswire.com/news-release/2023/05/31/2679178/0/en/Marker-Therapeutics-Reports-Pre-Clinical-Data-of-its-MT-601-MultiTAA-Specific-T-Cell-Product-Candidate-in-Lymphoma-Cells.html

May 31, 2023

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next